$Bio-Path(BPTH)$ Nice early setup for day two. The quote was $3.22 but they almost bumped it up to 6 lol power with the nano float. You can still continue. Analysis of potential market trends in the coming week is still good，Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $40 Price Target
$Bio-Path(BPTH)$ Are you going to buy a company like this: 1 million cash but 16 million operation loss as well as phase 1 success?as bad as this company is , i think this news will be a spike and then come down right away,You can buy this shell of a company for 3mm and then try to sell the IP for 5mm. If anyone will take it.Joke of a company!
$Bio-Path(BPTH)$ Company doesn’t have cash at the end of 2023 they only have 2.1 million, offering is coming.$2 M market cap for a company with potential Cancer cure ? Wow… this will go much much higher. start to cover,long term bullish!!go go go !!!buy!!
$Bio-Path(BPTH)$ Busted it for 1K from the 5 to 6 jump. Perfectly OK that I left another K+ on the table. Now moving on to the next opportunity.INVO yesterday, BPTH today. Wish I could figure out which one the hedge funds are going to play catch with next.same scam sugah heads...run up and now run down.....
$Bio-Path(BPTH)$ In February this was over 9.The news are top notch, the halt stopped a 300% jump, I hate to go long - but it is undervalued, maybe by 2:30pm it will bounce.want to short but my broker won't allow me to，Direct offering with a small amount of shares, stock target is $40, take a screenshot - this goes 12 next week.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
04-24
Public Prospectus
Form S-1 - General form for registration of securities under the Securities Act of 1933